Compound
GrantsAbout

2026 Compound

Compound
GrantsAbout
Back to Database
In vivo detoxification
Bio

In vivo detoxification

part of a healthy living

Concept

Reducing our intake of harmful chemicals can only do so much. Eventually we need to remove the chemicals we’ve ingested and need innovation here.

Longer Description

We are exposed to many products daily (pesticides, phthalates, bisphenols, PFAS) which have been linked to cancer, hormone dyregulation, lower sperm count, and others. However, tools to measure the accumulation of these substances let alone remove them are very limited. I think part of health and longevity should include our bodies being as toxin free as possible. We’ve seen efforts to reduce the amount of PFOS/PFAS remediation with Fixed Earth, BluumBio, Orin Technologies, Allonnia (A Ginkgo Bioworks Company) but think the in vivo remediation could accrue more value. It also dovetails with proactive healthcare which is becoming popularized with the longevity movement.

In order to meaningfully undertake toxin removal, we need to fidelitously measure toxins and their metabolites, understand where they’re accumulating, ID technologies for removal. Previous work shows that PFAS accumulates mostly in lung tissue, with other forever chemical derivitives enriching in the liver and bone. For inspiration, I tried looking at other toxin removal stragies - developing antibodies which bind the toxin of interest, filtering blood through an affinity column which binds the toxin, carbon nano structures, enzymatic nanoreactors, enzyme discovery, diet, and others.

Other Thoughts

  • Hard to understand which harmful chemicals to go after since we ingest so many. Ideally we would have a heirarchy.
  • People who menstruate could be at less risk to side effects as excretion of forever chemicals can go through menstrual fluid.
  • One could envision a prosumer market entry point as is the case for longevity clinics like Fountain Life, Hudson Health or others such as IV clinics. However, higher risk groups (such as those with kidney disease) could eventually go through clinical trials and insurance reimbursment.
  • Like longevity drugs, shorter-term endpoints based would need to be used. In places with socialized healthcare systems migt have a higher burden of proof - long studies would need to be conducted to calculate the differential quality adjusted life years (QALYs) to demonstrate utility.
  • Platforms for nanomaterial, enzyme, and/or delivery tech would be the most compelling from a venture-scale company perspective.

Comparable Companies

Related Reading

  • https://www.epa.gov/pfas/meaningful-and-achievable-steps-you-can-take-reduce-your-risk
  • https://bmcvetres.biomedcentral.com/articles/10.1186/s12917-014-0255-y
  • https://www.mdpi.com/2227-9059/10/4/784
  • https://www.sciencedirect.com/science/article/pii/S0021925820758205
  • https://onlinelibrary.wiley.com/doi/10.1002/imt2.7
  • https://actanaturae.ru/2075-8251/article/view/15681
  • https://pubag.nal.usda.gov/catalog/7763213
  • https://www.hindawi.com/journals/jnme/2015/760689/
  • https://www.science.org/doi/10.1126/sciadv.aay9035
  • https://www.theguardian.com/us-news/2019/may/22/toxic-chemicals-everyday-items-us-pesticides-bpa
  • https://time.com/5744817/bpa-levels-in-humans/

Related Theses

Marketplaces Requiring Private Intelligence
01
AI/ML

Marketplaces Requiring Private Intelligence

For deals requiring human-like analysis and negotiation but can’t risk information leakage

Read
New bio data + AI businesses
02
Bio

New bio data + AI businesses

Full-stack business required when new data modalities come online

Read
Ozempic for Sleep
03
Bio

Ozempic for Sleep

A sleep-focused therapeutics startup

Read

2026 Compound